Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting pyruvate metabolism generates distinct CD8+ T cell responses to gammaherpesvirus and B lymphoma
Taewook Kang, Young-Kwang Usherwood, Julie A. Reisz, Sukrut C. Kamerkar, Rachel Culp-Hill, Owen M. Wilkins, Andreia F. Verissimo, Fred W. Kolling IV, Anton M. Hung, Shawn C. Musial, Pamela C. Rosato, Angelo D’Alessandro, Henry N. Higgs, Edward J. Usherwood
Taewook Kang, Young-Kwang Usherwood, Julie A. Reisz, Sukrut C. Kamerkar, Rachel Culp-Hill, Owen M. Wilkins, Andreia F. Verissimo, Fred W. Kolling IV, Anton M. Hung, Shawn C. Musial, Pamela C. Rosato, Angelo D’Alessandro, Henry N. Higgs, Edward J. Usherwood
View: Text | PDF
Research Article Immunology Metabolism

Targeting pyruvate metabolism generates distinct CD8+ T cell responses to gammaherpesvirus and B lymphoma

  • Text
  • PDF
Abstract

T cells rely on different metabolic pathways to differentiate into effector or memory cells, and metabolic intervention is a promising strategy to optimize T cell function for immunotherapy. Pyruvate dehydrogenase (PDH) is a nexus between glycolytic and mitochondrial metabolism, regulating pyruvate conversion to either lactate or acetyl-CoA. Here, we retrovirally transduced pyruvate dehydrogenase kinase 1 (PDK1) or pyruvate dehydrogenase phosphatase 1 (PDP1), which control PDH activity, into CD8+ T cells to test effects on T cell function. Although PDK1 and PDP1 were expected to influence PDH in opposing directions, by several criteria they induced similar changes relative to control T cells. Seahorse metabolic flux assays showed both groups exhibited increased glycolysis and oxidative phosphorylation. Both groups had improved primary and memory recall responses following infection with murine gammaherpesvirus-68. However, metabolomics using labeled fuels indicated differential usage of key fuels by metabolic pathways. Importantly, CD8+ T cell populations after B cell lymphoma challenge were smaller in both groups, resulting in poorer protection, which was rescued by glutamine and acetate supplementation. Overall, this study indicates that PDK1 and PDP1 both enhance metabolic capacity, but the context of the antigenic challenge significantly influences the consequences for T cell function.

Authors

Taewook Kang, Young-Kwang Usherwood, Julie A. Reisz, Sukrut C. Kamerkar, Rachel Culp-Hill, Owen M. Wilkins, Andreia F. Verissimo, Fred W. Kolling IV, Anton M. Hung, Shawn C. Musial, Pamela C. Rosato, Angelo D’Alessandro, Henry N. Higgs, Edward J. Usherwood

×

Figure 2

Enforced PDK1 or PDP1 expression induces higher metabolic capacity in CD8+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
Enforced PDK1 or PDP1 expression induces higher metabolic capacity in CD...
Metabolic profiles of CD8+ T cells expressing PDK1 and PDP1 were analyzed by Seahorse assay. Cells were cultured in vitro with IL-2 for 3 days and were analyzed for (A) oxygen consumption rate with mitostress assay for mitochondrial respiratory capacity and (B) glycoPER with glycolytic rate assay for glycolytic capacity. (C) Pdp1-transduced cells were incubated with the inhibitors of ME1 or cPEPCK for 1.5 hours before analysis by glycolytic rate assay with media control– and EV-transduced cells. (D) Basal, maximal OXPHOS, and spare respiratory capacity from A. (E) Basal, compensatory, and spare glycolytic capacity levels from B. Each experiment was repeated 3 times. n = 4–8 technical replicates per group; 1-way ANOVA corrected for multiple comparisons with Tukey’s multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001;****P < 0.0001. Data are mean ± SD. OCR, oxygen consumption rate; ECAR, extracellular acidification rate; ME1, malic enzyme 1; cPEPCK, cytosolic phosphoenolpyruvate carboxykinase; glycoPER, glycolytic proton efflux rate.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts